Hemab Therapeutics Secures $157 Million Series C to Advance Breakthrough Treatments for Rare…
Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic treatments for rare bleeding and thrombotic disorders, has raised $157 million in a heavily…
Read More...
Read More...
